What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Customer Stories
Anonymized accounts drawn from real PeptideXpo engagements, every name, geography, and number removed or rounded, but the procurement structure, timeline, and outcome preserved. Each story covers a different buyer type and a different commercial scenario.
A US Northeast compounding pharmacy was running its whole GLP-1 program on a single bulk-active vendor and feeling every wobble in that vendor's lead time. Bringing PeptideXpo on as a documented second source — not a replacement — gave the dispensing schedule slack it had never had.
Role for PeptideXpo
Qualified second source
Single-vendor dependency
Removed
Molecules qualified together
GLP-1 actives + adjacent SKUs
Recurring per-mg pricing
Lower end of prior range
Read the story
A multi-location EU aesthetic group had the brand and the patients but no formulation or regulatory capability to take its in-clinic GHK-Cu protocol onto a retail shelf. PeptideXpo's OEM workflow carried it from brand brief to a launch-ready finished product.
Engagement type
Finished-goods OEM
Brief → first shipment
Inside the marketing window
CPNP notification
Cleared without doc round-trip
Stability coverage
Accelerated + real-time
Read the story
An academic neuroscience lab had a promising custom sequence but no way to make enough of it, to a documented identity and purity standard, for the next phase of in vivo work. PeptideXpo's custom-synthesis route closed that gap on the lab's experimental timeline.
Material type
Non-catalog custom sequence
Analytical packet
Identity + purity + contaminant, per batch
Timeline impact
Experimental schedule kept intact
Repeat orders
Route on file, no re-qualification
Read the story
A regional distributor was watching margins erode because every competitor sourced the same generalist catalog from the same wholesalers. Building a documentation-backed peptide line with PeptideXpo, on a forecast-based supply arrangement, gave it a position the others couldn't simply re-buy.
Shift
Commodity catalog → documented line
Competitive moat
Structure rivals can't re-buy
Line assembly
Several SKUs, one agreement
Releases
Ship-from-stock on forecast
Read the story
A pre-clinical group needed a research-tool peptide stacking several modifications most catalog providers won't combine. Where other quotes covered only part of the molecule, PeptideXpo took the whole thing — concept brief to validated material — on a research-program timeline.
What others offered
Part of the molecule
What PeptideXpo took on
Full modification stack
Identity evidence
Diagnostic mass shift per modification
Repeat orders
Route locked on quarterly forecast
Read the story
A first reply within 24 hours · Catalog · Sample COA · MOQ · Lead time. Our regulatory and sales teams read every inquiry before any price goes out.
